ByrneCDTargherG. NAFLD: A multisystem disease. J Hepatol2015; 62: s47–s64.
2.
StahlEPDhindsaDSLeeSK, et al.Non-alcoholic fatty liver disease and the heart. J Am Coll Cardiol2019; 73: 948–963.
3.
MachadoMCortez-PintoH. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol2014; 20: 12956–12980.
4.
BenedictMZhangX. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol2017; 9: 715–732.
5.
MotamedNRabieeBPoustchiH, et al.Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol2017; 41: 31–38.
6.
TempleJLCorderoPLiJ, et al.A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci2016; 17: 947–947.
7.
BhatiaLSCurzenNPCalderPC, et al.Non-alcoholic fatty liver disease: A new and important cardiovascular risk factor?Eur Heart J2012; 33: 1190–1200.
8.
FedericoADallioMMasaroneM, et al.The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction. Eur Rev Med Pharmacol Sci2016; 20: 4731–4741.
9.
LauridsenBKStenderSKristensenTS, et al.Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J2018; 39: 385–393.
10.
RuscicaMFerriNMacchiC, et al.Liver fat accumulation is associated with circulating PCSK9. Ann Med2016; 48: 384–391.
11.
DongiovanniPRomeoSValentiL. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int2015; 1: 1–10.
12.
DongiovanniPStenderSPietrelliA, et al.Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med2018; 283: 356–370.
13.
MacchiCBanachMCorsiniA, et al.Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiol2019; 26: 930–949.
14.
GepnerYShelefIKomyO, et al.The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol2019; 71: 379–388.
15.
DongiovanniPPettaSMannistoV, et al.Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol2015; 63: 705–712.
16.
DibbaPLiAAPerumpailBJ, et al.Emerging therapeutic targets and experimental drugs for the treatment of NAFLD. Diseases2018; 6: 1–15–1–15.
17.
Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093–1100.
18.
Keating NM, O'Malley AJ and Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448–4456.
19.
Lakshman R, Forouhi NG, Sharp SJ, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab 2009; 94: 4953–4960.
20.
Bonnet F, Irving K, Terra JL, et al. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis 2005; 178: 339–344.
21.
Van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study. Arthritis Res Ther 2006; 8: 1–6.
22.
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Eng J Med 2005; 352: 1092–1102.
23.
Stenvinkel P. Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268: 456–467.
24.
Kvetny J, Heldgaard PE, Bladbjerg EM, et al. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) 2004; 61: 232–238.
25.
Hooi JD, Stoffers HEJH, Kester ADM, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease: The Limburg PAOD Study. Scand J Prim Health Care 1998; 16: 177–182.
26.
Schürks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ 2009; 339: b3914.
27.
Islam F, Wu J, Jansson J, et al. Cardiovascular disease and HIV. HIV Med 2012; 13: 453–468.
28.
Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014; 65: 968–978.
29.
Gacci M, Corona G, Sebastianelli A, et al. Male lower urinary tract symptoms and cardiovascular events: A systematic review and meta-analysis. Eur Urol 2016; 70: 788–796.
30.
McClintic BR, McClintic JI, Bisognano JD, et al. The relationship between retinal microvascular abnormalities and coronary heart disease: A review. Am J Med 2010; 123: 374.e1–374.e7.
31.
De Hert M, Detraux J and Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 2018; 20: 31–40.
